Theravance Biopharma (TBPH) Says TD-1473 Well Tolerated in Phase 1 Clinical Trial
Tweet Send to a Friend
Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the Company's Phase 1 clinical trial of TD-1473, a novel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
